Entropy Neurodynamics (ASX:ENP) — Material Events
ASX:ENP · 13 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Entropy Neurodynamics Advances World-First Psilocin Trial for Binge Eating DisorderMedium
Entropy Neurodynamics advances TRP-8803 clinical trial for BED, raises $6.1M, and rebrands
30 Jan 2026
·Quarterly Activities Report
·85
Entropy Neurodynamics Files New US Patent to Strengthen TRP-8803 IBS Therapy IPMedium
Entropy Neurodynamics files new US patent to advance TRP-8803 IBS therapy following strong Phase 2a results
5 May 2026
·Patent Filing Announcement
·85
Entropy Neurodynamics Secures Patent to Protect TRP-8803’s Precision IV Psychedelic TherapyMedium
Entropy Neurodynamics secures Australian patent for TRP-8803 IV dosing method, strengthening IP through 2042
12 Feb 2026
·Patent Grant Announcement
·85
Entropy Neurodynamics Validates Psychedelic Therapy with 80% Drop in Binge EatingMedium
Entropy Neurodynamics reports 80% sustained reduction in binge eating from Phase 2a trial of oral psilocybin, validating lead IV psilocin asset
13 Jan 2026
·Clinical Trial Results Announcement
·85
Entropy Neurodynamics Advances Controlled Psychedelic Therapy in Binge Eating Disorder TrialMedium
Entropy Neurodynamics doses third patient in TRP-8803 BED trial achieving controlled psychedelic response
14 Apr 2026
·Clinical Trial Update
·85
Entropy Neurodynamics Advances Psychedelic Therapy with $6.1M Raise and Clinical MilestonesMedium
Entropy Neurodynamics reports reduced half-year loss, advances TRP-8803 clinical trial, raises $6.1M
27 Feb 2026
·Appendix 4D Half-year report
·85
Entropy’s TRP-8803 Shows Early Promise in Treating Binge Eating DisorderMedium
Entropy Neurodynamics Reports Promising Early Clinical Results for TRP-8803 in Binge Eating Disorder
22 Jan 2026
·Clinical Trial Update
·85
Entropy Neurodynamics Doses First Patient in Groundbreaking IV Psilocin BED TrialMedium
Entropy Neurodynamics doses first patient in pioneering IV psilocin BED trial
2 Dec 2025
·Clinical Trial Update
·85
Entropy Neurodynamics Reports Promising Early Results in TRP-8803 BED Trial and Secures Patent ProtectionMedium
Entropy Neurodynamics advances TRP-8803 clinical trial with positive early results and secures patent protection
28 Apr 2026
·Quarterly Activities Report
·85
Entropy Neurodynamics Advances Psychedelic Therapy with First Patient Dosing CompleteMedium
Entropy Neurodynamics completes first patient dosing in TRP-8803 Binge Eating Disorder trial
16 Dec 2025
·Clinical Trial Update
·75
Entropy Neurodynamics Completes Dosing in First Cohort of IV Psilocin BED TrialMedium
Entropy Neurodynamics completes first cohort dosing in Phase 2 BED trial of TRP-8803
2 June 2026
·Clinical Trial Update
·70
Entropy Neurodynamics Secures $1.73M Boost for Psychedelic Therapy TrialsMedium
Entropy Neurodynamics Receives $1.73M R&D Tax Incentive Refund for FY25
5 Mar 2026
·R&D Tax Incentive Receipt Announcement
·65
No articles in this tier for the last 12 months.
Market Mentions
11
- appeared in market wrap coverage
These are market wrap articles where Entropy Neurodynamics (ASX:ENP) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 23 (1 June -> 5 June) 2026
6 June 2026
Market Wrap - Week 19 (4 May -> 8 May) 2026
9 May 2026
Healthcare Wrap - Week 19 (4 May -> 8 May) 2026
9 May 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026
18 Apr 2026
Healthcare Wrap - Week 10 (2 Mar -> 6 Mar) 2026
7 Mar 2026
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026
Healthcare Wrap - Week 7 (9 Feb -> 13 Feb) 2026
14 Feb 2026
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026
Healthcare Wrap - Week 4 (19 Jan -> 23 Jan) 2026
25 Jan 2026
Market Wrap - Week 3 (12 Jan -> 16 Jan) 2026
18 Jan 2026